Nyxoah S.A.

This article explains that analysts have reduced Nyxoah’s fair value estimate from about €9.0 to roughly €7.37 per share, reflecting more cautious assumptions around capital needs, valuation, and execution risk while still acknowledging progress in the Genio launch and U.S. net revenue trends. It highlights both bullish commentary on potential growth and material concerns such as legal challenges, significant cash burn, reimbursement uncertainties, and a limited eligible patient population, leading to a mixed, risk‑aware outlook.

Investing.com reports that Cantor Fitzgerald has reiterated an Overweight rating and $11.00 price target on Nyxoah, implying substantial upside from a share price near $3.08 and citing approximately 121.63% revenue growth over the last twelve months as evidence of early traction in U.S. commercialization. The note frames upcoming ACCCESS study results and the continued ramp of U.S. launch activities as key catalysts for 2026–2027, while emphasizing that repeat orders and execution on guidance will be critical indicators of commercial success and a source of risk if they disappoint.

Macroaxis provides a quantitative, risk‑centric review showing Nyxoah trading around $3.14 on March 14, 2026, with an estimated 59% probability of financial distress, negative risk‑adjusted returns over the prior 90‑day period, and modest small‑cap market capitalization and liquidity metrics. Despite these cautionary indicators, the page notes a consensus analyst rating of about 4.0 (Buy) from five covering firms and discusses Nyxoah’s financial strength, leverage, margins, ESG scores, and ownership profile to frame an ambiguous risk‑reward balance rather than a clear directional call.

Blank Capital Research’s February 2026 report assigns Nyxoah an “Avoid” rating with a composite score of 27.5/100, arguing that the stock sits in the bottom quintile of its universe on key factors, lacks a meaningful economic moat, and suffers from poor capital allocation that together point to a high probability of continued underperformance. The analysis stresses that Nyxoah trades at a premium to fundamental value, that profit drivers and margin data are unclear, and that a narrowing moat trend and weak momentum justify avoiding new positions and potentially reducing existing exposure.

This stock analysis piece presents Nyxoah as a compelling growth opportunity, highlighting an average analyst target price of about $11.07 versus a current price around $4.67, implying roughly 137% potential upside, along with revenue growth of about 55.8% and a consensus of four Buy ratings and one Hold. It also acknowledges significant issues such as negative EPS, very weak return on equity, and sizeable negative free cash flow but ultimately frames the Genio system, analyst sentiment, and market expansion prospects as reasons why risk‑tolerant healthcare investors might view the stock favorably.

KoalaGains’ five‑part report, updated on November 4, 2025, describes Nyxoah as a highly speculative, cash‑burning, single‑product company whose future depends on a binary outcome—FDA approval and successful commercialization of the Genio system—and concludes the shares are overvalued with a poor risk‑reward profile and best treated as a watchlist position at most. Benchmarking Nyxoah against Inspire Medical Systems, ResMed, and LivaNova, the analysis highlights minimal revenue, rapidly shrinking cash balances, ongoing dilution, deeply negative margins, and the lack of a durable competitive moat, arguing that value‑oriented investors like Buffett or Munger would avoid the stock until it demonstrates sustainable profitability and a clear edge.